These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27638632)

  • 1. Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia.
    Soltani I; Gharbi H; Hassine IB; Bouguerra G; Douzi K; Teber M; Abbes S; Menif S
    Funct Integr Genomics; 2017 May; 17(2-3):263-277. PubMed ID: 27638632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
    Yap E; Norziha ZA; Simbun A; Tumian NR; Cheong SK; Leong CF; Wong CL
    Leuk Res; 2017 Aug; 59():32-40. PubMed ID: 28544907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
    Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
    Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate.
    Martins JRB; Moraes LN; Cury SS; Capannacci J; Carvalho RF; Nogueira CR; Hokama NK; Hokama POM
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy.
    Li YL; Tang JM; Chen XY; Luo B; Liang GH; Qu Q; Lu ZY
    Hum Cell; 2020 Jul; 33(3):610-618. PubMed ID: 32342278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance.
    Soltani I; Douzi K; Gharbi H; Benhassine I; Teber M; Amouri H; Ben Hadj Othman H; Farrah A; Ben Lakhel R; Abbes S; Menif S
    Hematology; 2017 May; 22(4):201-207. PubMed ID: 27825294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells.
    Yang Y; Zhong F; Jiang J; Li M; Yao F; Liu J; Cheng Y; Xu S; Chen S; Zhang H; Xu Y; Huang B
    Hematology; 2023 Dec; 28(1):2244856. PubMed ID: 37594290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.
    Ohyashiki K; Umezu T; Katagiri S; Kobayashi C; Azuma K; Tauchi T; Okabe S; Fukuoka Y; Ohyashiki JH
    Int J Mol Sci; 2016 Apr; 17(4):570. PubMed ID: 27092489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line.
    Bhutra S; Lenkala D; LaCroix B; Ye M; Huang RS
    PLoS One; 2014; 9(12):e115003. PubMed ID: 25506832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells.
    Agatheeswaran S; Pattnayak NC; Chakraborty S
    Sci Rep; 2016 Sep; 6():32493. PubMed ID: 27586591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
    Roy M; Sarkar R; Mukherjee A; Mukherjee S
    Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
    BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.
    Maral S; Bakanay SM; Yikilmaz AS; Dilek I
    J Cancer Res Ther; 2018; 14(6):1431-1433. PubMed ID: 30488870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.
    Toman O; Kabickova T; Vit O; Fiser R; Polakova KM; Zach J; Linhartova J; Vyoral D; Petrak J
    Oncol Rep; 2016 Sep; 36(3):1258-68. PubMed ID: 27430982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.